These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12629767)

  • 1. [Blood antioxidant capacity in gout].
    Tsutsumi Z; Yamamoto T
    Nihon Rinsho; 2003 Jan; 61 Suppl 1():465-9. PubMed ID: 12629767
    [No Abstract]   [Full Text] [Related]  

  • 2. Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update.
    Borghi C; Narkiewicz K; Mancia G
    Cardiol J; 2019; 26(1):99-101. PubMed ID: 30882192
    [No Abstract]   [Full Text] [Related]  

  • 3. [Our experience in the treatment of hyperuricemia with a xanthine oxidase inhibitor (HPP), Allopurinol].
    Rapado Errazti A
    Rev Esp Reum Enferm Osteoartic; 1966 Oct; 11(8):304-6. PubMed ID: 5997999
    [No Abstract]   [Full Text] [Related]  

  • 4. Gout management: let's get it right this time.
    Sundy JS
    Arthritis Rheum; 2008 Nov; 59(11):1535-7. PubMed ID: 18975368
    [No Abstract]   [Full Text] [Related]  

  • 5. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of gout.
    Goldfinger SE
    N Engl J Med; 1971 Dec; 285(23):1303-6. PubMed ID: 4941493
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative study of the xanthine oxidase inhibitors allopurinol and oxipurinol in man.
    Chalmers RA; Krömer H; Scott JT; Watts RW
    Clin Sci; 1968 Oct; 35(2):353-62. PubMed ID: 5721238
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug treatment of gout.
    Kelley WN; Wyngaarden JB
    Semin Drug Treat; 1971 Sep; 1(2):119-47. PubMed ID: 4949305
    [No Abstract]   [Full Text] [Related]  

  • 9. [Allopurinol in the treatment of hyperuricemia and chronic gout].
    Benedetti A; Nardini A; Busonera G
    Clin Ter; 1968 Apr; 45(2):141-54. PubMed ID: 5736585
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of gout with allopurinol. (Study of 106 cases)].
    Delbarre F; Auscher C; Amor B; de Géry A
    Sem Hop; 1967 Feb; 43(10):634-43. PubMed ID: 4292982
    [No Abstract]   [Full Text] [Related]  

  • 11. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure.
    Mellin V; Isabelle M; Oudot A; Vergely-Vandriesse C; Monteil C; Di Meglio B; Henry JP; Dautreaux B; Rochette L; Thuillez C; Mulder P
    Eur Heart J; 2005 Aug; 26(15):1544-50. PubMed ID: 15872033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat.
    Zhang Y; Chan MM; Andrews MC; Mori TA; Croft KD; McKenzie KU; Schyvens CG; Whitworth JA
    Am J Hypertens; 2005 Jul; 18(7):910-6. PubMed ID: 16053986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allpurinol in the treatment of hyperuricemia and chronic gout].
    Benedetti A; Nardini A; Busonera G
    Rev Clin Esp; 1969 Mar; 112(6):141-54. PubMed ID: 5347028
    [No Abstract]   [Full Text] [Related]  

  • 15. Febuxostat versus allopurinol for gout.
    Lustberg ME
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16598054
    [No Abstract]   [Full Text] [Related]  

  • 16. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress.
    George J; Struthers AD
    Vasc Health Risk Manag; 2009; 5(1):265-72. PubMed ID: 19436671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allopurinol as a therapeutic option in cardiovascular disease.
    Okafor ON; Farrington K; Gorog DA
    Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased hepatosplanchnic antioxidant uptake during hepatic ischaemia/reperfusion in patients undergoing liver resection.
    van de Poll MC; Dejong CH; Fischer MA; Bast A; Koek GH
    Clin Sci (Lond); 2008 Apr; 114(8):553-60. PubMed ID: 17995452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel thiazolo-pyrazolyl derivatives as xanthine oxidase inhibitors and free radical scavengers.
    Beedkar SD; Khobragade CN; Chobe SS; Dawane BS; Yemul OS
    Int J Biol Macromol; 2012 May; 50(4):947-56. PubMed ID: 22349546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.